Type1 Diabetes Mellitus Clinical Trial
Official title:
A Randomized, Double-blind, Single-dose, 2-Treatment, 2-Period, 2-Sequence Crossover Bioequivalence Study Comparing Two Formulations of Insulin Glulisine (Insulin Glulisine 300 Units/mL Versus Insulin Glulisine 100 Units/mL Marketed as Apidra® 100 Units/mL) Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
Verified date | April 2022 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary Objective: To demonstrate bioequivalence between insulin glulisine given as 300 Units/mL test formulation and insulin glulisine 100 Units/mL reference formulation after a single subcutaneous (SC) dose. Secondary Objectives: - To assess the pharmacodynamic (PD) profiles and further pharmacokinetic (PK) characteristics of insulin glulisine U300 in comparison to insulin glulisine U100 after a single SC dose. - To assess safety and tolerability of the test and the reference formulation of insulin glulisine.
Status | Completed |
Enrollment | 44 |
Est. completion date | May 3, 2017 |
Est. primary completion date | May 3, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion criteria : - Male or female subjects with type 1 diabetes mellitus (T1DM) for more than 1 year. - Total insulin dose of <1.2 U/kg/day. - Fasting negative serum C-peptide (<0.30 nmol/L). - Glycohemoglobin at screening (HbA1c) =9%. - Subjects with anti-insulin antibody titer at screening =30.0 kU/L. - Stable insulin regimen for at least 2 months prior to study. - Normal findings in medical history and physical examination (cardiovascular system, chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and musculoskeletal system), vital signs, electrocardiogram (ECG), and safety laboratory. Exclusion criteria: - Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic (apart from T1DM), hematological, neurological, psychiatric, systemic (affecting the body as a whole), ocular, gynecologic (if female), or infectious disease; any acute infectious disease or signs of acute illness or any history or presence of heparin induced thrombocytopenia Type II (HIT-type II). - Severe hypoglycemia resulting in coma/seizures or requiring assistance of another person, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit. - Frequent severe headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month). - Symptomatic hypotension (whatever the decrease in blood pressure), or asymptomatic postural hypotension defined by a decrease in systolic blood pressure equal to or greater than 20 mmHg within three minutes when changing from the supine to the standing position. - Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. - Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol. - Any medication (including medicine containing St John's Wort) within 14 days before inclusion (for systemic glucocorticoids within 3 months) or within 5 times the elimination half-life or PD half-life of the medication, with the exception of insulin, stable treatment (at least 2 months) with thyroid hormones, lipid-lowering and antihypertensive drugs and if female with the exception of hormonal contraception or menopausal hormone replacement therapy. - Positive reaction to any of the following tests: hepatitis B surface (HBs Ag) antigen, anti hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Country | Name | City | State |
---|---|---|---|
Germany | Investigational Site Number 276001 | Neuss |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of PK parameter: maximum observed insulin concentration | 10 hours | ||
Primary | Assessment of PK parameter: area under the concentration time curve | 10 hours | ||
Secondary | Assessment of PK parameter: time to reach Cmax (INS-tmax) | 10 hours | ||
Secondary | Assessment of PK parameter: terminal half-life (INS-t1/2z) | 10 hours | ||
Secondary | Assessment of PD parameter: area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 10 hours (GIR-AUC0-10) | 10 hours | ||
Secondary | Assessment of PD parameter: maximum smoothed body weight standardized GIR (GIRmax) | 10 hours | ||
Secondary | Assessment of PD parameter: time to GIRmax (GIR-tmax) | 10 hours | ||
Secondary | Duration of blood glucose control under clamp conditions - time | 10 hours | ||
Secondary | Number of patients with treatment emergent adverse events | 9 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03623113 -
The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes
|
N/A | |
Withdrawn |
NCT03396484 -
Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT03117998 -
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
|
Phase 2 | |
Recruiting |
NCT03369821 -
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
|
||
Completed |
NCT03202732 -
DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes
|
N/A | |
Completed |
NCT03704818 -
Dapagliflozin Effects on Hypoglycemia
|
Phase 1 | |
Recruiting |
NCT03864991 -
Lifestyle Changes and Glycemic Control in T1D
|
N/A | |
Completed |
NCT03725657 -
Correlation Between Exercise and Insulin Dose in a Camp for Pediatric Type 1 Patients
|
||
Completed |
NCT02985866 -
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
|
N/A | |
Completed |
NCT03003806 -
Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study
|
N/A | |
Withdrawn |
NCT04147637 -
FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia
|
N/A | |
Completed |
NCT03970889 -
Real-time Reminders To Decrease Late or Missed Meal Boluses
|
N/A | |
Recruiting |
NCT04589325 -
Ixekizumab Diabetes Intervention Trial (I-DIT)
|
Phase 2 | |
Completed |
NCT03367390 -
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
|
Phase 1 | |
Completed |
NCT03738852 -
Mechanisms for Restoration of Hypoglycemia Awareness
|
Early Phase 1 | |
Completed |
NCT03406585 -
Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT03859856 -
Ovarian Reserve in Diabetes Mellitus
|
||
Withdrawn |
NCT04102202 -
BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus
|
Phase 1/Phase 2 | |
Terminated |
NCT03353792 -
Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients
|
N/A | |
Recruiting |
NCT03811470 -
China Diabetes Registry by Metabolic Management Center
|